Contact
Search
Our Company
Leadership Team
Careers
Grants & Sponsorships
Expanded Access
Contact Us
Programs & Pipeline
Programs
Pipeline
Resources
For Patients & Providers
Mitochondria & Disease
Mitochondrial Diseases
Community
Contact Us
Scientific Data
Publications
Presentations
Investors & News
About
Stock Information
Reports & Filings
News
Publications
IR Presentations
Events
Corporate Governance
Contact Us
Reports
Email Alerts
Contact Us
Investors & News
Latest News
June 1,2021
Stealth BioTherapeutics Receives Orphan Drug Designation from the European Medicines Agency for Elamipretide for the Treatment of Barth Syndrome
May 28,2021
Stealth BioTherapeutics to Present at Jefferies Virtual Healthcare Conference
All News
Stock Quote (MITO)
Share
Why invest?
Our Company
Stealth BioTherapeutics is an innovative biopharmaceutical company developing therapies to treat mitochondrial dysfunction associated with genetic mitochondrial diseases and common diseases of aging.
Our Programs
We are investigating our lead product candidate in late stage clinical studies in three primary mitochondrial diseases – primary mitochondrial myopathy, Barth syndrome and Leber’s hereditary optic neuropathy – as well as an earlier stage clinical study in dry age-related macular degeneration.
Our Pipeline
We continue to expand our broad knowledge of mitochondrial biology and novel chemistries, and advance our mitochondrial platform of late-stage clinical programs and pipeline candidates.
Latest Reports
May 18, 2021
Form 6-K : Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16
HTML
April 30, 2021
Form 6-K : Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16
HTML
Reports
Latest Presentations
June 03, 2021
Investor Presentation June 2021
May 18, 2021
First Quarter 2021 Financial Results Earnings Call
Presentations
Events
June 01, 2021
Jefferies Healthcare Conference at 3:00 p.m. ET.
Webcast
May 26, 2021
UBS Global Healthcare Virtual Conference at 10:00 am ET
Webcast
Financial Calendar
Media Relations
Amelia Stetler, 617-762-2562
media@stealthbt.com
Investor Inquiries
Stern IR
Janhavi Mohite, 212-362-1200
IR@stealthbt.com
